TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03101514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanglaite
Description: Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
Study: NCT02503774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.
Study: NCT03720366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2 Probes
Description: digoxin and rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 3 probes
Description: pioglitazone
Study: NCT01596478

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Motivational Behavior Therapy
Description: Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-week wait list
Description: Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
Study: NCT06346002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: The MBI program implemented comprised ten weekly sessions. Please refer to the arm/group descriptions for further details.
Study: NCT02503774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.
Study: NCT01673698

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReShape Duo balloon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diet counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise counseling

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise counseling
Study: NCT00877357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shan 5
Description: Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
Study: NCT02503774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arms' description.
Study: NCT00877357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shan 5
Description: Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shan 5
Description: Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
Study: NCT01912638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ologen Collagen Matrix
Description: Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provisc
Description: Provisc is an cohesive viscoelastic.
Study: NCT01510574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 3 x 200mcg tablets of oral misoprostol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 x placebo tablets resembling misoprostol taken orally
Study: NCT01937702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl (sodium chloride)
Study: NCT00043602

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard interpersonal psychotherapy (IPT)
Description: Participants will receive 12 sessions of IPT over 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician managed interpersonal psychotherapy (CM-IPT)
Description: Participants will receive 12 sessions of CM-IPT over 1 year.
Study: NCT02503774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arms' description.
Study: NCT00194025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
Study: NCT00448760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenously, 25 mg/m2, over 30 minutes, 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
Study: NCT03659578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
Study: NCT00448760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously, 85 mg/m2, over 2 hours, 2 cycles

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Microarray analysis
Description: Analysis of tumor for pathologic response to protocol therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Analysis of tumor for pathologic response to protocol therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Surgical removal of tumor for correlative studies
Study: NCT01911234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF-Kinoid
Description: IM administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration
Study: NCT03659578

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: split-course radiotherapy
Description: Patient was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break of four weeks. Patients without disease progression had a dose of 15 Gy in 5 fractions or 24 Gy in 6 fractions as a boost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymosin alpha 1
Description: subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
Study: NCT00624845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS103HP
Description: Maximum 6 bags of OMS103HP irrigation solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Maximum of 6 bags of vehicle irrigation solution
Study: NCT02356237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No episiotomy
Description: Avoidance of episiotomy
Study: NCT03886480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaeboVR
Description: Use of the SaeboVR rehabilitation system for approximately 1 hour, 3 times per week for 4 weeks. Each intervention session will consist of the participant engaging in a series of virtual occupations involving their affected upper extremity and will include a 5 minute warm up activity followed by 3, 15 minute sessions of virtual occupation practice separated by 2, 5 minute breaks. The virtual occupations will include: grocery shopping, grocery storage, breakfast preparation, pet shopping, pet feeding, pet bathing, garden planting, garden harvesting, dinner preparation, closet organizing, and soup kitchen volunteering.
Study: NCT02296320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI4893
Description: Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI4893
Description: Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
Study: NCT03074994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-articular TXA (15 mg/kg)
Description: combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarticular TXA 2 g (40 mL)
Description: inject separate from multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 75 mL)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area
Description: (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
Study: NCT02031614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Withdrawal of 500 mL of whole blood.
Study: NCT01900366

Intervention type: PROCEDURE
Intervention: Fat Biopsy
Description: Fat biopsy

Intervention type: PROCEDURE
Intervention: Fat Biopsy
Description: Fat biopsy
Study: NCT03074994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TXA 40 mL inject into intraaricular knee capsule
Description: after multimodal local anesthetic infiltration (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to tourniquet deflation
Study: NCT03187860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial Biopsy
Description: Bronchial biopsies will be performed on all subjects.
Study: NCT00530530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: oral
Study: NCT03187860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALI culture
Description: Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALI culture
Description: Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALI culture
Description: Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALI culture
Description: Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
Study: NCT02497716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939
Description: Single dose of reconstituted rivaroxaban granules
Study: NCT05623553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
Study: NCT02556138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORBERA Intragastric Balloon
Description: The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
Study: NCT01541631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel and Albendazole
Description: Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40mg/kgBWT Albendazole - 400mg once
Study: NCT00530530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: oral
Study: NCT02383160

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioventus Exogen 4000: Low-intensity pulsed ultrasound
Description: Active low-intensity pulsed ultrasound
Study: NCT05013489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and intercare based intervention
Description: Eight week online program based on mindfulness, compassion and intercare intervention. A two hour synchronic online session every week plus daily homework based on meditation and journaling exercises.~The topics covered in the program are mindfulness meditation, cognitive behavioral therapy exercises, gratitude and acceptance, compassion and self compassion exercises, conservation of resources theory and intercare.
Study: NCT00530530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03154151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive-Behavioral Therapy
Description: Each participant will complete writing assignments focusing on how their experiences during the 9/11 attacks or the WTC recovery effort continue to affect their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Supportive Therapy
Description: Each participant will complete writing assignments focusing on problems and stressors that are currently affecting their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
Study: NCT02383160

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Placebo device with no active therapy
Study: NCT02491879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: 2.5% Ketoprofen gel with a 2 g local use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel with a 2 g local use
Study: NCT01908283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugated vaccine (PCV13)
Description: Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugated vaccine (PCV13)
Description: Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
Study: NCT02967731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 Mometasone Furoate Sinus Drug Depot
Description: Management of Chronic Sinusitis
Study: NCT00662246

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: respiratory gated proton beam radiotherapy
Description: - Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
Study: NCT01737866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 423
Description: omecamtiv mecarbil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 423
Description: omecamtiv mecarbil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 423
Description: omecamtiv mecarbil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 423
Description: omecamtiv mecarbil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 423
Description: omecamtiv mecarbil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 423
Description: omecamtiv mecarbil
Study: NCT01541631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40mg/kgBWT Albendazole - 400mg once
Study: NCT00377910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aethoxysclerol
Description: 2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
Study: NCT03324789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Implant Partial Over-denture
Description: Single Implant Retained Partial Over-denture will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Partial Denture
Description: patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
Study: NCT02408744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
Study: NCT00089492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background ARVs
Description: As prescribed
Study: NCT01045421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237 (Alisertib)
Description: Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period.
Study: NCT00804141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-methylnaltrexone bromide (MOA-728)
Description: MOA-728 will be administered as per the dose and schedule specified in the arm.
Study: NCT05666947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: Eight weeks of home-based exercise programs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home-based exercise
Description: Eight weeks of home-based exercise programs
Study: NCT05378919

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 50 Gy
Description: Radiotherapy 50 Gy 5 radiations per week of 2 Gy for 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil/folic acid
Description: Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)
Description: oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 50 Gy
Description: Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy.~FOLOFX4 will be administrated for 8 cycles over a 16 week period. Patients will undergo re-staging within 6 weeks of their 8th cycle of FOLFOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 8 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous fluorouracil.